Mitochondrial-targeted therapeutics in oral squamous cell carcinoma: molecular and therapeutic implications - Takeaways - MDSpire

Mitochondrial-targeted therapeutics in oral squamous cell carcinoma: molecular and therapeutic implications

  • By

  • Saichao Zhou

  • Liye An

  • May 11, 2026

  • 0 min

Share

  • 1

    Oral squamous cell carcinoma (OSCC) is a prevalent malignancy linked to mitochondrial dysregulation and resistance to conventional therapies.

  • 2

    Key oncogenic drivers like TP53 mutations and EGFR amplification contribute to mitochondrial dysfunction and metabolic reprogramming in OSCC.

  • 3

    Mitochondrial DNA mutations in OSCC are associated with tumor progression, including increased risk of metastasis and altered respiratory function.

  • 4

    Therapeutic strategies targeting mitochondrial pathways may improve treatment outcomes, but face challenges like intratumoral heterogeneity.

  • 5

    A mechanism-driven approach is essential for developing mitochondria-targeted therapies in OSCC, emphasizing the need for predictive biomarkers.

Original Source(s)

Mitochondrial-targeted therapeutics in oral squamous cell carcinoma: molecular and therapeutic implications

  • by Saichao Zhou, Liye An

  • May 11, 2026

Related Content

Non-specific skin lesions in angioimmunoblastic T-cell lymphoma lead to diagnosis challenge: a case report and literature review

Prospective Evidence on Artificial Intelligence−Assisted Melanoma Diagnostics: A Systematic Review and

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report